Narrows Timing of Planned NDA Submission to the Third Quarter of 2019 Back-to-Back Publications in ‘The Lancet’ Highlight Positive Clinical Trial Results of Veverimer Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Tricida, Inc.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 1, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

TRCA-301E trial is the first, long-term, randomized, multicenter, blinded, placebo-controlled trial to evaluate the treatment of metabolic acidosis in patients with CKD SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 25, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 5, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 40 th Annual Health Care Conference on Wednesday, June 12, 2019 at 10:00 am PT . Gerrit Klaerner , Tricida’s Founder, President and Chief Executive

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 8, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 30, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2019 financial results after the close of market on Wednesday, May 8, 2019 . Tricida will host a conference call and webcast at 4:30 pm Eastern Time to

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 8, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced the closing of its previously announced public offering of 6,440,000 shares of its common stock at a public offering price of $36.00 per share, which includes the exercise in full by the

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced the pricing of its public offering of 5,600,000 shares of its common stock at a public offering price of $36.00 per share for total gross proceeds of $201.6 million , before deducting

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares in the offering will be sold by Tricida .

Blinded, randomized, placebo-controlled, 40-week extension trial, TRCA-301E, met its primary and all secondary endpoints, supporting the long-term safety and efficacy profile of TRC101 Patients treated with TRC101 showed a significant reduction in all-cause mortality and progression of CKD (defined